Vivus, Inc.: VVUS (NASDAQ)
Vivus in Washington Post Magazine:
washingtonpost.com
VIVUS, Inc. is a pharmaceutical company engaged in the development
of innovative therapies for the treatment of quality-of-life disorders
in men and women, with a focus on sexual dysfunction. Current
development programs target Female Sexual Dysfunction (FSD), Erectile
Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two
innovations in the treatment of erectile dysfunction, and has
partnered with Abbott Laboratories (NYSE:ABT) for the international
marketing and distribution of its male transurethral ED products. In
Canada, VIVUS has partnered exclusively with Paladin Labs (TSE:PLB) to
market and distribute MUSE.
CONTACT: VIVUS, Inc.
Richard Walliser, 650/934-5200
ir@vivus.com, www.vivus.com
or
VIVUS Media Contact --
Lisa Lindberg, 212/825-3210, theproteam@aol.com
or
Investor Relations --
Lippert/Heilshorn & Associates, Inc.
Bruce Voss/Jody Cain, 310/691-7100
bvoss@lhai.com / jcain@lhai.com |
